| A multi-center randomized phase II clinical study of bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for Chinese patients with metastatic colorectal cancer | |
| Cao, Ranhua; Zhang, Shuai; Ma, Dedong; Hu, Likuan | |
| 刊名 | MEDICAL ONCOLOGY
 |
| 2015 | |
| 卷号 | 32期号:1 |
| 关键词 | Chinese metastatic colorectal cancer Second-line chemotherapy FOLFIRI Bevacizumab |
| DOI | 10.1007/s12032-014-0325-9 |
| URL标识 | 查看原文 |
| 内容类型 | 期刊论文 |
| URI标识 | http://www.corc.org.cn/handle/1471x/4766458 |
| 专题 | 山东大学 |
| 作者单位 | 1.Shandong Univ, Qilu Hosp, Dept Radiat Oncol, Jinan 250012, Shandong, Peoples R China. 2.[Cao, Ran |
| 推荐引用方式 GB/T 7714 | Cao, Ranhua,Zhang, Shuai,Ma, Dedong,et al. A multi-center randomized phase II clinical study of bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for Chinese patients with metastatic colorectal cancer[J]. MEDICAL ONCOLOGY,2015,32(1). |
| APA | Cao, Ranhua,Zhang, Shuai,Ma, Dedong,&Hu, Likuan.(2015).A multi-center randomized phase II clinical study of bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for Chinese patients with metastatic colorectal cancer.MEDICAL ONCOLOGY,32(1). |
| MLA | Cao, Ranhua,et al."A multi-center randomized phase II clinical study of bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for Chinese patients with metastatic colorectal cancer".MEDICAL ONCOLOGY 32.1(2015). |
| 个性服务 |
| 查看访问统计 |
| 相关权益政策 |
| 暂无数据 |
| 收藏/分享 |
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
修改评论